New cell therapy trial aims to tame Tough-to-Treat bowel diseases
NCT ID NCT07309744
Summary
This early-stage study is testing the safety and initial effectiveness of a new type of cell therapy called RD06-05 for adults with moderate-to-severe ulcerative colitis or Crohn's disease. The therapy involves modifying a patient's own immune cells to target and reduce inflammation in the gut. It is designed for people whose disease has not been controlled by multiple standard biologic medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.